After several false starts, way is clear for John Thero to take Vascepa cholesterol drug to market
Drug firms questions whether it can afford to fund trial central to growth plans
Irish biopharma group regonised revenues of $5.5m from its new Vascepa drug in Q2
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices